“Our work is part of a growing effort to assess the implications of including race and ethnicity in clinical risk prediction models,” said lead investigator Quinn White, a biostatistics doctoral student at the University of Washington, Seattle.
News & Events
Latest
MESA heart disease risk score worked well with or without race included
American Heart Association Newsroom,
University of Washington Biostatistics staff member Maggie Tarnawa recently expanded her responsibilities as curriculum coordinator to include creating professional development programming for UW Biostatistics students. Learn more about the additional programs and resources Tarnawa has in the works for the upcoming year.
University of Washington researchers Sharon Browning and Seth Temple co-authored a study proposing new statistical methods for detecting signatures of strong natural selection that have occurred in humans in the past several thousand years.
Kendrick Li, PhD returned to UW as a guest presenter at the UW Biostatistics autumn seminar. Li graduated from the UW Biostatistics PhD program in 2021 and, after a postdoc at the University of Michigan, joined the faculty at St. Jude Children’s Research Hospital. Read our interview with Li.
Longer-term data from SWOG S1826 trial confirm nivolumab-AVD benefit in Hodgkin lymphoma
SWOG Cancer Research Network,
Two years after starting treatment, patients with stage 3-4 classic Hodgkin lymphoma treated with nivolumab plus AVD chemotherapy had roughly one-half the risk of progression or death of those who had a standard treatment of brentuximab vedotin plus AVD.
“This new analysis with more patient follow-up is critical to understanding the clinically meaningful benefit obtained from N-AVD compared to BV-AVD,” said Michael LeBlanc, PhD, lead biostatistician on the S1826 study and a UW professor of biostatistics.